The FDA has approved lifileucel for the treatment of certain adults with unresectable or metastatic melanoma, marking the first approval of a cellular therapy in the solid tumor setting. The tumor-derived autologous T-cell immunotherapy is indicated for patients previously treated with a PD-1–blocking antibody, and if BRAF V600–positive, a BRAF inhibitor with or without an MEK inhibitor. The approval was based on findings from a clinical trial showing an objective response rate of 31.5% in patients treated with lifileucel. The full prescribing information contains a boxed warning for treatment-related mortality and other risks. The therapy will be available at Stanford Medicine immediately. Monitoring for adverse reactions is crucial. Sharon Worcester is the author of the content.
Source link
FDA Approves First Cellular Therapy for Metastatic Melanoma
